Is mPGES-1 a promising target for pain therapy?
Cyclooxygenase (COX) inhibitors are widely used analgesic and anti-inflammatory drugs. Owing to undesirable effects caused by unselective COX inhibitors and selective COX-2 inhibitors, microsomal prostaglandin E(2) synthase-1 has been considered as an alternative target for the development of analgesic drugs. However, recent findings question the usefulness of this terminal synthase as a promising drug target for pain therapy.
Scholich
Klaus
K
Pharmazentrum Frankfurt, ZAFES, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. scholich@em.uni-frankfurt.de
Geisslinger
Gerd
G
D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019746:Intramolecular Oxidoreductases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008954:Models, Biological; D010146:Pain / Q000188:drug therapy* / Q000201:enzymology; D000071876:Prostaglandin-E Synthases
D016861:Cyclooxygenase Inhibitors; D019746:Intramolecular Oxidoreductases; C000605862:PTGES protein, human; D000071876:Prostaglandin-E Synthases